178 related articles for article (PubMed ID: 24435060)
1. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers.
Wheler JJ; Janku F; Falchook GS; Jackson TL; Fu S; Naing A; Tsimberidou AM; Moulder SL; Hong DS; Yang H; Piha-Paul SA; Atkins JT; Garcia-Manero G; Kurzrock R
Cancer Chemother Pharmacol; 2014 Mar; 73(3):495-501. PubMed ID: 24435060
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers.
Braiteh F; Soriano AO; Garcia-Manero G; Hong D; Johnson MM; Silva Lde P; Yang H; Alexander S; Wolff J; Kurzrock R
Clin Cancer Res; 2008 Oct; 14(19):6296-301. PubMed ID: 18829512
[TBL] [Abstract][Full Text] [Related]
3. Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies.
Falchook GS; Fu S; Naing A; Hong DS; Hu W; Moulder S; Wheler JJ; Sood AK; Bustinza-Linares E; Parkhurst KL; Kurzrock R
Invest New Drugs; 2013 Oct; 31(5):1192-200. PubMed ID: 23907406
[TBL] [Abstract][Full Text] [Related]
4. A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors.
Nelson BE; Tsimberidou AM; Fu X; Fu S; Subbiah V; Sood AK; Rodon J; Karp DD; Blumenschein G; Kopetz S; Pant S; Piha-Paul SA
Oncologist; 2023 Dec; 28(12):1100-e1292. PubMed ID: 37311055
[TBL] [Abstract][Full Text] [Related]
5. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC.
Munster P; Marchion D; Bicaku E; Lacevic M; Kim J; Centeno B; Daud A; Neuger A; Minton S; Sullivan D
Clin Cancer Res; 2009 Apr; 15(7):2488-96. PubMed ID: 19318486
[TBL] [Abstract][Full Text] [Related]
6. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.
Falchook GS; Wheler JJ; Naing A; Piha-Paul SA; Fu S; Tsimberidou AM; Hong DS; Janku F; Zinner R; Jiang Y; Huang M; Lin Q; Parkhurst K; Kurzrock R
Invest New Drugs; 2015 Feb; 33(1):215-24. PubMed ID: 25363205
[TBL] [Abstract][Full Text] [Related]
7. Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.
Aggarwal R; Thomas S; Pawlowska N; Bartelink I; Grabowsky J; Jahan T; Cripps A; Harb A; Leng J; Reinert A; Mastroserio I; Truong TG; Ryan CJ; Munster PN
J Clin Oncol; 2017 Apr; 35(11):1231-1239. PubMed ID: 28221861
[TBL] [Abstract][Full Text] [Related]
8. Phase I pharmacokinetic and pharmacodynamic evaluation of combined valproic acid/doxorubicin treatment in dogs with spontaneous cancer.
Wittenburg LA; Gustafson DL; Thamm DH
Clin Cancer Res; 2010 Oct; 16(19):4832-42. PubMed ID: 20705615
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial of oral ridaforolimus (AP23573; MK-8669) in combination with bevacizumab for patients with advanced cancers.
Nemunaitis J; Hochster HS; Lustgarten S; Rhodes R; Ebbinghaus S; Turner CD; Dodion PF; Mita MM
Clin Oncol (R Coll Radiol); 2013 Jun; 25(6):336-42. PubMed ID: 23615181
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).
Bullock KE; Petros WP; Younis I; Uronis HE; Morse MA; Blobe GC; Zafar SY; Gockerman JP; Lager JJ; Truax R; Meadows KL; Howard LA; O'Neill MM; Broadwater G; Hurwitz HI; Bendell JC
Cancer Chemother Pharmacol; 2011 Feb; 67(2):465-74. PubMed ID: 21079958
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics.
Nwankwo N; Zhang Z; Wang T; Collins C; Resta L; Ermisch S; Day J; Decker R; Kornberg L; Nicol S; Thornton D; Armstrong DK; Carducci MA
Invest New Drugs; 2013 Jun; 31(3):653-60. PubMed ID: 22766773
[TBL] [Abstract][Full Text] [Related]
12. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.
Fu S; Hou MM; Naing A; Janku F; Hess K; Zinner R; Subbiah V; Hong D; Wheler J; Piha-Paul S; Tsimberidou A; Karp D; Araujo D; Kee B; Hwu P; Wolff R; Kurzrock R; Meric-Bernstam F
Ann Oncol; 2015 May; 26(5):1012-1018. PubMed ID: 25669829
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer.
Chu BF; Karpenko MJ; Liu Z; Aimiuwu J; Villalona-Calero MA; Chan KK; Grever MR; Otterson GA
Cancer Chemother Pharmacol; 2013 Jan; 71(1):115-21. PubMed ID: 23053268
[TBL] [Abstract][Full Text] [Related]
15. An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer.
Gordon MS; Robert F; Matei D; Mendelson DS; Goldman JW; Chiorean EG; Strother RM; Seon BK; Figg WD; Peer CJ; Alvarez D; Adams BJ; Theuer CP; Rosen LS
Clin Cancer Res; 2014 Dec; 20(23):5918-26. PubMed ID: 25261556
[TBL] [Abstract][Full Text] [Related]
16. Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study.
Merchan JR; Qin R; Pitot H; Picus J; Liu G; Fitch T; Maples WJ; Flynn PJ; Fruth BF; Erlichman C
Cancer Chemother Pharmacol; 2015 Mar; 75(3):485-93. PubMed ID: 25556030
[TBL] [Abstract][Full Text] [Related]
17. A phase I trial of vatalanib (PTK/ZK) in combination with bevacizumab in patients with refractory and/or advanced malignancies.
Jones SF; Spigel DR; Yardley DA; Thompson DF; Burris HA
Clin Adv Hematol Oncol; 2011 Nov; 9(11):845-52. PubMed ID: 22252616
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma.
Drappatz J; Lee EQ; Hammond S; Grimm SA; Norden AD; Beroukhim R; Gerard M; Schiff D; Chi AS; Batchelor TT; Doherty LM; Ciampa AS; Lafrankie DC; Ruland S; Snodgrass SM; Raizer JJ; Wen PY
J Neurooncol; 2012 Mar; 107(1):133-8. PubMed ID: 21984064
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
Daud AI; Dawson J; DeConti RC; Bicaku E; Marchion D; Bastien S; Hausheer FA; Lush R; Neuger A; Sullivan DM; Munster PN
Clin Cancer Res; 2009 Apr; 15(7):2479-87. PubMed ID: 19318485
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.
Strickler JH; McCall S; Nixon AB; Brady JC; Pang H; Rushing C; Cohn A; Starodub A; Arrowood C; Haley S; Meadows KL; Morse MA; Uronis HE; Blobe GC; Hsu SD; Zafar SY; Hurwitz HI
Invest New Drugs; 2014 Apr; 32(2):330-9. PubMed ID: 24173967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
